Home » Posts tagged with » Eli Lilly and Company
Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. Currently, Lilly is studying various potential neutralizing antibodies for the prevention and/or treatment of the novel coronavirus as monotherapy or in combination. Through the collaboration, the two US pharma companies […]

Continue reading …
Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study

Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom from migraine attacks at 60 minutes and up to 48 hours. According to the US pharma giant, adults who were given Reyvow […]

Continue reading …
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt

Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]

Continue reading …
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib is an oral JAK1/JAK2 inhibitor, which was licensed by Lilly from Incyte. Marketed as OLUMIANT, baricitinib has approval in […]

Continue reading …
Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with the investigational antibody LY-CoV555 for the treatment of COVID-19. LY-CoV555 is the first antibody candidate to emerge from Lilly’s collaboration with AbCellera Biologics, which was announced in March 2020, with […]

Continue reading …
Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo (selpercatinib) capsules for the treatment of three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. The approvals are for the drug to be used in patients whose tumors […]

Continue reading …
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]

Continue reading …
Lilly bags Trulicity FDA approval for reducing CV risk in type 2 diabetes patients

Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Trulicity (dulaglutide) to reduce major cardiovascular events (MACE) in type 2 diabetes patients having established cardiovascular (CV) disease or multiple cardiovascular risk factors. The latest FDA approval Trulicity means that the drug the first […]

Continue reading …
Lilly to build $470m pharma manufacturing plant in North Carolina

US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 million for producing injectable products and delivery devices. The new Lilly pharma manufacturing facility will be built in Research Triangle Park, and will generate over 460 new jobs in Durham. […]

Continue reading …
Page 1 of 3123